A real-world study of more than 11 000 patients with polycythemia vera identified persistent gaps in hematocrit control and substantial treatment burden, with thromboembolic events associated with mean all-cause health care costs exceeding...
A real-world study of more than 11 000 patients with polycythemia vera identified persistent gaps in hematocrit control and substantial treatment burden, with thromboembolic events associated with mean all-cause health care costs exceeding...
A US population-based study of more than 63 000 patients with myeloproliferative neoplasms identified improved survival in primary myelofibrosis alongside persistent differences in incidence and survival across disease subtypes, age groups,...
A US population-based study of more than 63 000 patients with myeloproliferative neoplasms identified improved survival in primary myelofibrosis alongside persistent differences in incidence and survival across disease subtypes, age groups,...
Researchers found that among patients with myelofibrosis (MF), anemia was associated with reduced doses of ruxolitinib and worse survival outcomes, highlighting the need for proactive strategies aimed at mitigating the impact and progression...
Researchers found that among patients with myelofibrosis (MF), anemia was associated with reduced doses of ruxolitinib and worse survival outcomes, highlighting the need for proactive strategies aimed at mitigating the impact and progression...
Researchers found that sustained exposure to full-dose ruxolitinib was associated with spleen reduction and manageable toxicity among select patients with myelofibrosis (MF).
Researchers found that sustained exposure to full-dose ruxolitinib was associated with spleen reduction and manageable toxicity among select patients with myelofibrosis (MF).
A post hoc analysis of the JUMP clinical trial found that anemia medications can be used in combination with ruxolitinib among patients with myelofibrosis without compromising treatment effectiveness.
A post hoc analysis of the JUMP clinical trial found that anemia medications can be used in combination with ruxolitinib among patients with myelofibrosis without compromising treatment effectiveness.
Monitoring spleen and hematologic responses in patients with ruxolitinib-treated polycythemia vera (PV) enabled researchers to develop a prognostic model that may help physicians identify patients at increased risk of poor outcomes.
Monitoring spleen and hematologic responses in patients with ruxolitinib-treated polycythemia vera (PV) enabled researchers to develop a prognostic model that may help physicians identify patients at increased risk of poor outcomes.
Researchers found upfront JAK2 testing to be more cost-effective in US settings than the JAKPOT predication rule when identifying JAK2 mutations among patients with erythrocytosis.
Researchers found upfront JAK2 testing to be more cost-effective in US settings than the JAKPOT predication rule when identifying JAK2 mutations among patients with erythrocytosis.
Long-term tyrosine kinase inhibitors (TKI) therapy has transformed chronic myeloid leukemia (CML) survival, but new findings suggest survivors may continue to experience substantial challenges with overall health, physical function, and...
Long-term tyrosine kinase inhibitors (TKI) therapy has transformed chronic myeloid leukemia (CML) survival, but new findings suggest survivors may continue to experience substantial challenges with overall health, physical function, and...
Recent advances in chronic myeloid leukemia are expanding treatment options and supporting a more individualized approach that balances molecular response, toxicity, treatment-free remission goals, comorbidities, and cost.
Recent advances in chronic myeloid leukemia are expanding treatment options and supporting a more individualized approach that balances molecular response, toxicity, treatment-free remission goals, comorbidities, and cost.
A new economic analysis suggests that insured patients with chronic myeloid leukemia (CML) may face similar annual out-of-pocket costs across tyrosine kinase inhibitor options, despite substantially higher treatment costs for many...
A new economic analysis suggests that insured patients with chronic myeloid leukemia (CML) may face similar annual out-of-pocket costs across tyrosine kinase inhibitor options, despite substantially higher treatment costs for many...
